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Molecular Genetics of Drug-resistance in Epilepsies
Nearly one-third of newly diagnosed patients with epilepsy remain unresponsive to 
antiepileptic drugs (AEDs), etiopathogenesis of which is poorly understood. The genes 
encoding the proteins that regulate the pharmacokinetics such as P-glycoprotein 
[ABCBI], major vault protein [MVP gene] and drug metabolizing enzymes [ABCB1, 
ABCG2, MVP, CYP2C9, CYP2C19, CYP3A4, CYP3A5, EPHX1, UGT1A1, UGT2B7], 
and pharmacodynamics such as sodium channels [SCN1A, SCN2A] and GABA 
receptors [GABRA1, GABRA6, GABRB2, GABRG2] of AEDs are under intense 
investigation to unravel the mysteries of AED-resistance.  However, till today, a 
consistent and reliable result that could help the clinician either to predict drug-
resistance or to overcome it has not been forthcoming. The discrepant results may be 
related to variations in the deﬁnition of drug-resistance, heterogeneous patient 
populations, ethnic variations in the frequency distribution of single nucleotide 
polymorphisms (SNPs) and the selection of SNPs. Understanding of these limitations 
of existing studies, hopefully, will help in designing better studies.
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Introduction
  E p i l e p s y  i s  a  c o m m o n 
neurological disorder and is a major 
public health concern, directly affecting 
an estimated 50 million people worldwide 
and involving an additional 500 million 
people as family members and caregivers 
o f  pa t i en t s  (1 ) .  I t  cons t i tu t e s  a 
heterogeneous group of disorders 
characterized by recurrent unprovoked 
epileptic seizures due to widely different 
etiologies with a prevalence rate of about 
5 per 1,000 and an annual incidence rate of 
about 50 per 100,000 (2). Although, a 
majority of patients with epilepsy are 
responsive to presently available 
antiepileptic drugs (AEDs), 20% to 30% 
of them continue to exhibit recurrent 
seizures, despite optimal AED therapy 
(3). Based on a conservative estimate, 
there will be more than ﬁve million people 
with active epilepsy in India, and of them, 
at least one million will be drug-resistant. 
Resource-poor countries are ill-equipped 
to tackle the enormous medical, social and 
economic challenges posed by drug-
resistant epilepsies (4)
Deﬁnition of drug-resistance
 It is generally agreed that an 
adequate trial of appropriate AEDs should 
be given before labeling the epilepsy as 
drug-resistant. However, the concept of 
adequate trial of AEDs is highly arbitrary. 
To overcome some of the ambiguity 
involved in deﬁning drug-resistant 
epilepsy, International League Against 
Epi lepsy ( ILAE) has  proposed a 
consensus deﬁnition of drug-resistant 
epilepsy (5). According to this deﬁnition, 
drug-resistant epilepsy is deﬁned as 
“failure of adequate trials of two tolerated 
and appropriately chosen and used AED 
schedules (whether as monotherapies or in 
combination) to achieve sustained seizure 
freedom”. Sustained seizure freedom is 
deﬁned as seizure freedom for a minimum 
of 12 months or for a period three times the 
previous longest seizure-free period, 
whichever is longer. The ILAE deﬁnition 
places a greater emphasis on seizure 
freedom, as this is the only meaningful 
outcome which can lead to improved 
quality of life of persons with epilepsy. 
This deﬁnition equally emphasizes the 
importance of appropriate and tolerated 
treatment schedules as treatment failures 
due to inappropriately chosen or non-
tolerated drugs, non-compliance to drugs 
or due to the unknown drug schedules 
cannot be classiﬁed as drug-resistant. 
Failure of two AEDs has been included in 
the deﬁnition with the recognition of the 
fact that once the patient fails two AED 
trials, subsequent chances of sustained 
seizure freedom from further AED trials 
are very unlikely (3). 
 Patients with drug-resistant 
epilepsy have considerable impairments 
in activities of daily living, education, 
employment and social interaction due to 
continuing seizures and AED side effects. 
These patients are at higher risk of 
developing various psychological 
problems like depression, anxiety and 
psychosis (6). Additional morbidity and 
mortality of continued seizures include 
accidental injury, cognitive decline and 
sudden death (7). Rates for employment, 
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marriage and fertility are considerably 
lower in patients with poorly controlled 
seizures (8,9). Patients with drug-resistant 
epilepsies account for nearly 80 percent of 
the annual cost attributable to epilepsy 
(10). A select group of patients with drug-
resistant epilepsy has a chance of 
becoming seizure-free with epilepsy 
surgery. However, a majority of them are 
not candidates for epilepsy surgery and 
will have to be continued on AED therapy 
with the hope of achieving seizure control.
Causes of drug-resistance
 Several clinical factors have been 
found to be associated with the drug-
resistance in patients with epilepsy, which 
include early seizure onset, number of 
seizures before the initiation of AED, high 
seizure burden within ﬁrst few months of 
starting AED, seizure clustering, family 
history of epilepsy, febrile seizures, 
electroencephalographic abnormalities, 
history of status epilepticus, demonstrable 
brain lesion on magnetic resonance 
imaging, remote symptomatic etiology, 
abnormal neurological status, traumatic 
brain injury, and psychiatric comorbidity 
(11,12). However, a signiﬁcant proportion 
of patients may not have any one of the 
above attributes to associate with drug-
resistance. Perhaps, the most important 
determinant of AED response/resistance 
is the epilepsy syndromic diagnosis. 
While an idiopathic epilepsy syndrome 
like juvenile myoclonic epilepsy responds 
very well to AED therapy, the syndrome of 
mesial temporal lobe epilepsy with 
hippocampal sclerosis (MTLE-HS) is 
very resistant to AED. Moreover, the 
pattern of the drug-resistance observed 
also varies; de novo, where patients might 
be resistant right from the starting of AED 
therapy, progressive drug resistance, 
where patients become resistant in due 
course of disease progression and a third 
type, waxing and waning resistance, 
where active epilepsy is interrupted by 
periods of remission (13). Conceptually, 
the variable response to AEDs can be 
attributed to factors related to altered 
p h a r m a c o k i n e t i c  f a c t o r s  a n d 
pharmacodynamic factors inﬂuencing 
their efﬁcacy and tolerability. 
Putat ive  mechan i sms  o f  drug-
resistance
  The clinical efﬁcacy of an AED 
depends on its absorption, distribution 
and elimination, which in turn is 
inﬂuenced by the physicochemical 
properties of the drug (Figure 1). Most of 
the AEDs are lipophilic and penetrate the 
biomembranes by passive diffusion. The 
activity of the efﬂux transporters in the 
gastrointestinal tract and blood-brain-
barrier inﬂuence the absorption and brain 
u p t a k e  o f  A E D s ,  r e s p e c t i v e l y. 
Furthermore, the altered targets of AEDs 
may affect the clinical efﬁcacy. In 
addition, the differential activity of the 
drug metabolizing enzymes, which are 
substrates for AEDs, inﬂuences drug 
efﬁcacy and tolerability.  To understand 
the genetics of drug-resistance, three 
major hypotheses have been proposed 
(Figure 1).These mechanisms are not 
mutually exclusive; they can occur 
together in an individual patient and can 
collectively contribute to drug-resistance.
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Transporter hypothesis
  A c c o r d i n g  t o  t r a n s p o r t e r 
hypothes i s ,  d rug- res i s tance  i s  a 
consequence of increased expression or 
function of multidrug transporter 
p r o t e i n s ,  s o  t h a t  s u f ﬁ c i e n t 
intraparenchymal AED concentrations 
are not attained at their targets, even in the 
presence of adequate serum AED levels. 
This notion has been supported by the 
characterization of different efﬂux 
transporter proteins that function as drug 
efﬂux pumps at the blood-brain-barrier, 
gastrointestinal tract and other privileged 
environments (14,15). The genes that 
encode efﬂux transporters are highly 
conserved and the vast majority of them 
belong to the super family of adenosine 
triphosphate-binding cassette (ABC) 
p r o t e i n s .  S i n g l e  n u c l e o t i d e 
polymorphisms (SNPs) of the encoding 
genes of efﬂux transporters, including P-
glycoprotein (p-gp) (ABCB1), and other 
members of the multidrug resistance-
associated protein family (ABCC/MRP 
family) and breast cancer resistance 
protein (BCRP) (ABCG2/BCRP) can 
theoretically affect the function of the 
blood–brain barrier and for this reason 
been widely studied in context of AED-
resistance (14,15).
Target hypothesis
  To exert its pharmacological 
effect, AED after successfully crossing 
the blood-brain-barrier, should reach its 
target. Currently available AEDs act on a 
relatively smaller number of targets. The 
major targets of the AEDs are voltage-
gated sodium channels, calcium channels 
and neurotransmitter systems (GABA and 
glutamate). Voltage-gated sodium 
channels form the targets for a majority of 
ﬁrst-line AEDs. According to target 
hypothesis, drug-resistance can be caused 
by the modiﬁcation of one or more AED 
target molecules resulting in reduced 
efﬁcacy of a given AED (16).
Role of drug metabolizing enzymes and 
other factors in drug-resistance
  An array of enzymes is involved 
in the biotransformation of AEDs. Drug 
Figure 1: A schematic illustration of the mechanisms involved in inter-individual variability in drug-response.
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metabolism is accomplished by two 
phases, where the most common reaction 
involving phase I enzymes (cytochrome 
P450 family of mixed function oxidases) 
is hydroxylation. Phase 2 metabolism 
involves various conjugation reactions 
that increase hydrophilicity and facilitate 
renal excretion of drug. A genetic 
variation with a very high enzymatic 
activity may be associated with poor drug 
response in conventional dosages (13,16). 
Molecular Genetics of Drug-resistance
  The molecular targets with 
respect  to above described three 
hypotheses are depicted in Figure 2. 
Although several of these targets have 
come under intense investigations, it 
should be admitted that, till today, a 
consistent and reliable result that could 
help the clinician either to predict drug-
resistance or to overcome it has not been 
forthcoming. What follows is a critical 
appraisal of the molecular genetic studies 
on AED-resistance, including my own. 
These studies can be broadly grouped into 
those inquiring genetic variations in the 
pharmacokinetic and pharmacodynamic 
aspects of AEDs (Table 1).
  Over the last ﬁve years, the author 
and his colleagues at the R. Madhavan 
Nayar Center for Comprehensive 
Epilepsy Care, in collaboration with the 
Rajiv Gandhi Center for Biotechnology, 
Trivandrum, has undertaken a series of 
molecular genetic studies with respect to 
AED-responsiveness/resistance. We 
studied several genes related to AED 
p h a r m a c o k i n e t i c s  a n d 
pharmacodynamics  among  th ree 
homogeneous groups of subjects: 200 
drug-resistant epilepsy (MTLE-HS), 200 
drug-responsive epilepsy (juvenile 
myoclonic epilepsy) and 200 non-
epilepsy controls from south Indian 
population of Kerala. We screened 29 
SNPs from 10 genes involved in AED 
Figure 2 : A schematic illustration of the candidate genes for studies on drug-resistance.
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pharmacokinetics (ABCB1, ABCG2, 
MVP, CYP2C9, CYP2C19, CYP3A4, 
CYP3A5, EPHX1, UGT1A1, UGT2B7) 
and 13 SNPs from 6 genes involved in 
pharmacodynamics of AED (SCN1A, 
SCN2A, GABRA1, GABRA6, GABRB2, 
GABRG2), totaling 42 SNPs from 16 
genes.  We selected these SNPs based on 
their functional signiﬁcance or by the 
tagging status to uncover maximum 
variation in the genes of interest. 
Table 1 : Classiﬁcation of phamacogenetics of drug-body interaction with regard 
to antiepileptic drug-resistance
Protein / Receptor Gene
Pharmacokinetic Interaction
P-glycoprotein
Breast cancer resistance protein
Major vault protein
Metabolizing enzymes
Phase I
Phase II
Pharmacodynamic interaction
Voltage gated sodium channel
GABA receptor
 
ABCB1
ABCG2
MVP 
CYP2C9, CYP2C19, CYP3A4, CYP3A5, EPHX1
UGT1A1, UGT2B7
SCN1A, SCN2A
GABRA1, GABRA6, GABRB2, GABRG2
G e n e s  i n v o l v e d  i n  A E D 
pharmacokinetics P-glycoprotein 
(ABCB1)
  The gene encoding p-gp, ABCB1, 
is the maximally investigated gene with 
respect to AED-resistance (Aronica, 
2012). An initial study in 2003 showed a 
signiﬁcant association of a synonymous 
variant (C3435T) of ABCB1 with 
multidrug resistant epilepsy (17). 
However, a series of studies that followed, 
including ours, failed to consistently 
replicate such an association. We found 
that subjects carrying ABCB1 rs1922242 
polymorphism had ﬁve times higher risk 
of  developing corpora  amylacea 
accumulation in the hippocampus, 
compared to those MTLE-HS patients 
without this polymorphism (18). In 
addition to its function as an efﬂux 
t r anspo r t e r,  t he  ro l e  o f  CoA in 
sequestration of toxic cellular metabolites 
is being increasingly recognized (19). 
Therefore, upregulation of p-gp function 
in patients with uncontrolled seizures 
might be a consequence rather than the 
cause of seizures (20). Two recent meta-
analyses on AED-resistance and ABCB1 
genotype, both having over 3000 drug-
resistant epilepsy patients and controls 
across multiple populations, revealed no 
Kurupath Radhakrishnan
12Molecular genetics of drug-resistance in epilepsies
signiﬁcant association between the 
ABCB1 C3435T genotype and resistance 
to AEDs (21,22). 
Breast cancer resistance protein 
(ABCG2)
  A limited number of studies have 
investigated genetic variations in 
ABCG2, which codes for the BCRP. The 
non-synonymous polymorphisms, 
rs2231142 (C421A) and rs2231137 
(G34A) have been associated with 
decreased BCRP express ion and 
decreased BCRP transporter activity, 
respectively (23,24). In our study, three 
functional variants of ABCG2 were 
screened and the data did not identify any 
signiﬁcant association between these 
polymorphisms and response to AED 
treatment. Similarly, a Korean study and a 
Chinese study on multidrug-resistant 
epilepsy patients revealed no association 
of drug-resistance with ABCG2 gene 
(23,24). 
Major vault protein (MVP gene) 
 
 Recent studies have associated an 
intracellular organelle called vaults 
(named so because of their resemblance to 
vaulted ceilings in cathedrals) with 
multidrug resistance in cancer cells 
(25,26). Vaults are localized mainly in the 
cytoplasm, but a small fraction also 
resides at the nuclear membrane and the 
nuclear pore complex. Although the exact 
function of vaults remains unknown, 
several lines of evidence indicate that they 
are involved in intracellular vesicular and 
bidi rec t ional  nucleo-cytoplasmic 
transports (25,26).  Over expression of 
MVP has been reported in brain tissue 
samples from rat model of drug-resistant 
temporal lobe epilepsy, AED-resistant 
  
human MTLE-HS, frontal lobe epilepsy,
and focal epilepsies due to benign 
neoplasm (27,28). We compared the 
distribution of three SNPs of the MVP 
gene,  rs4788187,  rs3815824 and 
rs3815823, among cohorts of AED-
resistant and responsive patients and non-
epileptic controls (29). To our knowledge, 
ours is the ﬁrst study that inquired the 
association of genetic variants of MVP 
gene with AED resistance.  However, the 
resul t s  revealed  tha t  r s4788187, 
rs3815824, rs3815823 variants of MVP 
gene were associated neither with 
predisposition for epilepsy nor with AED-
resistance in the population we studied 
(29).
Drug metabolizing enzymes
  The Phase I and Phase II drug 
metabolizing enzymes are major players 
in determining AED pharmacokinetics. 
The author studied the functional 
po lymorph i sms  in  Phase  I  d rug 
metabol iz ing enzymes (CYP2C9, 
CYP2C19, CYP3A4, CYP3A5, EPHX1) 
and Phase II (UGT1A1, UGT2B7) drug 
metabolizing enzymes. Studies have 
reported the association of genetic 
variations in drug metabolizing enzymes 
with dosage requirement of commonly 
prescr ibed AEDs (30) .  I t  can be 
hypothesized that patients with over-
expression of metabolizing enzymes are 
more likely to become drug-resistant 
during the course of AED treatment than 
with slow metabolizer phenotype, which 
require lesser drug doses to control 
seizures. However, we could not observe 
any signiﬁcant association of functional 
v a r i a n t s  p e r t a i n i n g  t o  A E D 
response/resistance. The frequency 
distribution of the variants among the 
MTLE-HS and juvenile myoclonic 
epilepsy cohorts was similar to that of the 
normal Kerala population.  In a study from 
North India, the frequency of a variant 
genotype (CYP2C9*1/*3), which is 
known to result in slow metabolizer 
phenotype, was found signiﬁcantly lower 
in drug-resistant group as compared to 
drug-responsive group (31). With respect 
t o  E P H X 1 ,  i n v o l v e d  i n  t h e 
biotransformation of carbamazepine, we 
did not ﬁnd a signiﬁcant difference in the 
frequency of the alleles among the AED-
resistant and responsive epilepsy patients. 
The distribution of the SNP frequencies in 
the present study differed from those 
reported in other Indian studies, which can 
be attributed to the differences in the 
phenotypic classiﬁcation of the drug-
resistant and responsive epilepsies. The 
frequency of the extensive metabolizer 
(EM) TT genotype,  in termedia te 
metabolizer (IM) CT genotype and poor 
metabolizer (PM) CC genotype of 
rs1051740 in epilepsy patient groups 
pooled together in our study were 41%, 
42.2% and 16.8%, respectively, which is 
different from the frequency distribution 
of North Indian epilepsy patients of 43.5% 
TT, 41.6% CT and 14.9% CC genotypes 
(32). However, the distribution of EM and 
IM genotypes, when pooled together, 
were similar in both populations. The 
frequency of EM, IM and PM of 
rs1051740, in AED-resistant group were 
41.1%, 44.7% and 14.2% and in AED-
responsive group, the distribution was 
40.9%, 39.4% and 19.7%, respectively. In 
case of rs2234922, frequency of EM GG 
genotype is higher (8.8%) in the pooled 
epilepsy samples, AED resistant (7.3%) 
and AED responsive (10.5%), when 
compared to the data from the North 
Indian epilepsy samples (32).  
G e n e s  i n v o l v e d  i n  A E D 
pharmacodynamics
  Studies that have investigated the 
role of target genes have concentrated on 
genes encoding voltage-gated sodium 
channels and GABA  receptors. 
A
Voltage-gated sodium channel genes
  Voltage-gated sodium channels 
are primarily involved in the generation of 
action potentials and also the high 
frequency ﬁring in epileptic discharges. 
With the notion that nucleotide variations 
in the genomic region coding AED 
binding domains, DIIIS6 and DIVS6 
segments of the NaV1.1 channel, can 
affect the drug binding and thereby drug 
response, we selected SNPs from SCN1A. 
Additionally, we genotyped three SNPs of 
SCN2A that were found to be associated 
with AED-resistance in the Chinese 
population (33). The results showed that 
there was no association of the studied 
SNPs with drug-resistance. Our results 
were contradictory to the initial report and 
were aligning with other studies (33,36), 
with the exception of a study from Japan 
which demonstrated a signiﬁcant 
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association between the rs3812718 AA 
genotype and carbamazepine-resistant 
epilepsy (34). Additionally our study also 
showed, the variant rs3812718 increases 
the  suscep t ib i l i t y  to  MTLE-HS, 
independently without increasing the 
susceptibility to the febrile seizures (35).
GABA receptor genes
  In a rodent model of drug-
resistant temporal lobe epilepsy, altered 
GABA receptor subunit expression and 
differential drug response has been 
observed (36). We probed the role of 
functional variants in GABRA1, GABRA6, 
GABRB2, GABRG2 receptor subtype 
genes for its contribution to the AED-
resistance in Kerala population. Although 
we found no association of these variants 
with respect to AED-resistance, the 
variant rs211037 in GABRG2 showed an 
a s s o c i a t i o n  w i t h  t h e  i n c r e a s e d 
predisposition to develop epilepsy. 
Previous reports from North Indian 
epilepsy patients (37) and in Caucasians 
epilepsy patients (38,39) did not show any 
involvement of GABRG2 rs211037 
synonymous variant with epilepsy.
Putative causes for the discrepant 
results
  Despite the large volume research 
undertaken during last one decade in 
epilepsy pharmcogenetics, translation to 
clinical utility has been very limited, to 
date, with the exception of a strong 
association between HLA-B*1502 and  
carbamazepine-induced Stevens-Johnson 
syndrome and toxic epidermal necrolysis 
in Han Chinese people (40).  The 
discrepant results can be accounted for a 
variety of factors such as variations in the 
deﬁnition of the drug resistance, 
heterogeneous patient populations, ethnic 
variations in the distribution of the SNPs 
and the selection of SNPs.
Variation in the deﬁnition of AED-
resistant epilepsies
  The lack of consensus among the 
different study groups in deﬁning the 
drug-resistance might have resulted in the 
inclusion of the patients deﬁned as drug-
resistant in one study as drug-responsive 
in another, and thereby inﬂuencing the 
results of the genetic association. 
Generally, in clinical practice, AED-
resistance is deﬁned as seizure recurrence 
despite the trial of two to three AEDs or 
surgical intervention for seizure control, 
and drug responsiveness as seizure 
freedom on AEDs for a certain period of 
time. In studies reviewed here, the number 
of seizures and duration have varied 
widely from no seizures for one year, one 
seizure in 6 months, ≥1 seizure in a month, 
≥1 seizure in a year, ≥4 seizures in 6 
months to one year, >10 seizures in a year, 
> 2 seizures in 2years, and 50% reduction 
of seizures in a year. The AED-responsive 
cohort has been deﬁned more or less 
uniform throughout the studies mainly as 
seizure freedom for >1 years, although 
certain studies have deﬁned >6 months to 
2 years of seizure freedom. Hopefully, 
future studies are likely to adhere to the 
recent ILAE deﬁnition of AED-resistant 
epilepsy (5).
Heterogeneity of epilepsy phenotype
  A  m a j o r i t y  o f  t h e 
pharmacogenetic studies in epilepsies 
conducted till now have included a variety 
of epilepsy syndromes together by 
ignor ing  the  under ly ing  d i sease 
pathobiology (41). Since epilepsy 
syndromes are highly heterogeneous with 
respect to age at onset, seizure type, 
pathogenesis and AED responsiveness, 
comparison of molecular genetic results 
from heterogeneous samples becomes 
difﬁcult (42). 
Population stratiﬁcation
  Population stratiﬁcation can 
results in the non-replicability of genetic 
association studies, which can be deﬁned 
as occurrence of subpopulations for the 
studied populations that have different 
allele frequencies for the candidate gene 
studied. This disparity in frequencies 
arises because each population has a 
unique genetic and social history, and thus 
ancestral patterns of geographical 
migration, mating practices, reproductive 
expansions  and bot t lenecks ,  and 
stochastic variation all yield differences in 
allele frequencies between individuals 
(43). Thus the differential risk of a trait for 
the subpopulation and its inclusion in a 
study population can confound the 
association between the candidate gene 
and the disease. The issue of the 
population stratiﬁcation and admixture 
effects can be addressed by matching  
geographical region (at study design 
stage) and by ancestry information 
markers (at analysis stage).
Biased selection of functional variants
  The lack of association can also 
be attributed to the biased selection of 
functional variants, which may not be 
tagging the true causal variants. Since the 
selection of tagged SNPs to uncover 
maximum variation are based on the 
HapMap database with reference to 
Caucasian and Gujarati Indians, subtle 
difference may occur in the linkage 
disequilibrium pattern with respect to 
studied population of Kerala, which 
affects the tagging status and information 
content of the selected SNPs. Further, the 
small effect size of the common variants in 
explaining a small fraction of variability 
and heritability of the complex traits 
makes then clinically negligible. 
Future perspectives
  Future studies should attempt to 
rectify the problems of existing literature 
b y  a s s e m b l i n g  u n i f o r m  p a t i e n t 
populations, especially with respect to 
drug-resistance and epilepsy syndromic 
diagnosis. With the slashing of the cost of 
genotyping technologies, studies should 
undertake high density genotyping to 
identify the common variants and whole 
genome sequencing to identify the rare 
variants with high effect size (44). Further, 
better statistical analysis methods, which 
accounts for all potential confounding 
factors, have to be developed to enhance 
the accuracy of the results. With the rapid 
progress being made in the ﬁeld of 
pharmacogenetics, hopefully, we will in 
the near future be able to identify patients 
with drug-resistant epilepsy early and 
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consider alternate treatment options. 
Further, genomic information will enable 
the clinician to prescribe syndrome 
speciﬁc AED therapy with optimum 
dosage for efﬁcacy and with minimum 
adverse drug reaction, thereby paving way 
to individualized management of persons 
with epilepsy.
Acknowledgments
  The author wish to thank Dr. 
Moinak Banerjee, in whose laboratory at 
t h e  R a j i v  G a n d h i  C e n t e r  f o r 
B io t echno logy,  Tr ivandrum,  the 
molecular research work was undertaken. 
A major part of this research has emanated 
through the untiring effort of Dr. Shabeesh 
Balan, who did his PhD thesis under my 
guidance. This work was supported by 
research grants from Board of Research in 
Nuclear Sciences, Department of Atomic 
Energy, Government of India and from the 
Kerala State Council  for Science 
Te c h n o l o g y  a n d  E n v i r o n m e n t , 
Government of Kerala. 
References
1. World Health Organization (2005). 
Atlas. Epilepsy Care in the World. 
Geneva : WHO Press, 20-24.
2. Sander JW, Shorvon SD (1996). 
Epidemiology of the epilepsies. J 
Neurol Neurosurg Psychiatry 61: 433-
443.
3. Kwan P, Brodie MJ (2000). Early 
identiﬁcation of refractory epilepsy. N 
Engl J Med 342:314–319.
4.   Radhakrishnan K (2009). Challenges 
in the management of epilepsy in 
resource-poor countries. Nat Rev 
Neurol 5: 323-330.
5.  Kwan P, Arzimanoglou A, Berg AT, et 
al .  (2010) .  Deﬁnit ion of  drug 
resistantepilepsy: consensus proposal 
by the ad hoc Task Force of the ILAE 
C o m m i s s i o n  o n  T h e r a p e u t i c 
Strategies.Epilepsia 51:1069-1077.
6.  Torta R, Keller R (1999). Behavioral, 
psychotic, and anxiety disorders in 
epilepsy: etiology, clinical features, 
and  the rapeu t i c  impl ica t ions . 
Epilepsia 40 (Suppl 10):S2-S20.
7.  Sperling MR, Feldman H, Kinman J, 
Liporace JD, O'Connor MJ (1999). 
Seizure control and mortality in 
epilepsy. Ann Neurol 46: 45–50.
8.  Varma NP, Sylaja PN, George L, Sarma 
PS,  Radhakr i shnan  K (2007) . 
Employment concerns of people with 
epilepsy in Kerala, south India. 
Epilepsy Behav 10:250-254.
9. Santosh D, Kumar TS, Sarma PS, 
Radhakrishnan K (2007). Women with 
Onset of Epilepsy Prior to Marriage: 
Disclose or Conceal? Epilepsia 
48:1007-1010.
10. Begley CE, Famulari M, Annegers JF, 
et al. (2000). The cost of epilepsy in 
the United States: an estimate from 
population-based clinical and survey 
data. Epilepsia 41: 342–351.
11. Regesta G, Tanganelli P (1999). 
Clinical aspects and biological bases of 
drug-resistant epilepsies. Epilepsy Res 
34: 109-122.
12. Johnson MR, Tan NC, Kwan P, Brodie 
MJ (2011). Newly diagnosed epilepsy 
and pharmacogenomics research: A 
step in the right direction? Epilepsy 
Behav 22: 3-8.
13. Schmidt D, Löscher W (2005). Drug 
resistance in epilepsy: putative 
n e u r o b i o l o g i c  a n d  c l i n i c a l 
mechanisms. Epilepsia 46: 858-877.
14. Löscher W, Potschka H (2005). Role of 
drug efﬂux transporters in the brain for 
drug disposition and treatment of brain 
diseases. Prog Neurobiol 76: 22-76.
15. Aronica E, Sisodiya S, Gorter J (2012). 
C e r e b r a l  e x p r e s s i o n  o f  d r u g 
transporters in epilepsy. Adv Drug 
Deliv Rev 64: 919-929.
16. Remy S, Beck H (2006). Molecular 
a n d  c e l l u l a r  m e c h a n i s m s  o f 
pharmacoresistance in epilepsy. Brain 
129 : 18-35.
17. Siddiqui A, Kerb R, Weale ME et al. 
(2003). Association of multidrug 
res i s t ance  in  ep i l epsy  wi th  a 
polymorphism in the drug-transporter 
gene ABCB1.N Engl J Med 348: 1442-
1448.
1 8 . D a s  A ,  B a l a n  S ,  M a t h e w  A , 
Radhakrishnan VV, Banerjee M, 
Radhakrishnan K (2011). Corpora 
amylacea in the hippocampus of 
patients with mesial temporal lobe 
epilepsy: A new role for an old gene. 
Ind J Hum Genet 17 (Suppl. 1): S41-
S47.
19.Cavanagh JB (1999) .  Corpora 
a m y l a c e a  a n d  t h e  f a m i l y  o f 
poyglycosan diseases. Brain Res Rev. 
29: 265-295.
20 .Das A,  Balan  S ,  Baner jee  M, 
R a d h a k r i s h n a n  ( 2 0 11 ) .  D r u g 
resistance in epilepsy and ABCB1 
gene: The clinical perspective. Ind J 
Hum Genet 17 (Suppl. 1): S12-S21.
21. Bournissen FG, Moretti ME, Juurlink 
DN, Koren G, Walker  M,  Finkelstein 
Y (2009). Polymorphism of the 
M D R 1 / A B C B 1  C 3 4 3 5 T 
drug transporter and resistance to 
a n t i c o n v u l s a n t  d r u g s :  A 
meta analysis. Epilepsia 50: 898-903.
22. Haerian B, Roslan H, Raymond A, et 
a l .  ( 2 0 1 0 ) .  A B C B 1  C 3 4 3 5 T 
polymorphism and the r isk of 
resistance to antiepileptic drugs in 
epilepsy: A systematic review and 
meta-analysis. Seizure 19: 339-346.
23. Kim DW, Lee SK, Chu K, et al. (2009). 
Lack of association between ABCB1, 
A B C G 2 ,  a n d  A B C C 2  g e n e t i c 
polymorphisms and mul t idrug 
resistance in partial epilepsy. Epilepsy 
Res 84:86-90.
24. Ieiri I (2011). Functional signiﬁcance 
17 Kurupath Radhakrishnan
18Molecular genetics of drug-resistance in epilepsies
of genetic polymorphisms in P-
glycoprotein (MDR1, ABCB1) and 
breast cancer resistance protein 
(BCRP,  ABCG2).  Drug Metab  
Pharmacokinet 27: 85-105.
25. Mossink MH, van Zon A, Scheper RJ, 
Sonnerveld P, Wiemer AC (2003). 
Vaults : a ribonucleoproten particle 
involved in drug resistance? Oncogene 
22: 7458-7467.
26. Van Zon A, Mossink MH, Scheper RJ, 
Sonnerveld P, Wiemer EAC (2003). 
The vault complex. Cell Mol Life Sci 
60: 1828-1837.
27. van Vliert EA, Aronica E, Redeker S, 
Gorter JA (2004). Expression and 
celluar distribution of major valut 
protein : a putative marker for 
pharmacoresistance in a rat model for 
temporal lobe epilepsy. Epilepsia 45: 
1506-1516.
28. Sisodiya SM, Martinian L, Scheffer 
GL, et al. (2003) Major vault protein, a 
marker  o f  d rug  res i s tance ,  i s 
upregulated in refractory epilepsy. 
Epilepsia 44 : 1388-1396.
29. Balan S, Lekshmi S, Sathyan S, Vijai J, 
Banerjee M, Radhakrishnan K (2013). 
Major vault protein (MVP) gene 
polymorphisms and drug resistance in 
mesial temporal lobe epilepsy and 
hippocampal sclerosis. Gene 526 : 
449-453. 
30. Tate SK, Depondt C, Sisodiya SM, et 
al. (2005). Genetic predictors of the 
maximum doses patients receive 
during clinical use of the anti-epileptic 
drugs carbamazepine and phenytoin. 
Proc Natl Acad Sci USA 102: 5507-
5512.
31. Lakhan R, Kumari R, Singh K, Kalita 
J, Misra UK, Mittal B (2011). Possible 
role of CYP2C9 and CYP2C19 single 
nucleotide polymorphisms in drug 
refractory epilepsy. Ind J Med Res 134: 
295-301.
32. Grover S, Gourie-Devi M, Baghel R, et 
al. (2010) Genetic proﬁle of patients 
with epilepsy on ﬁrst-line antiepileptic 
drugs and potential directions for 
p e r s o n a l i z e d  t r e a t m e n t . 
Pharmacogenomics 11: 927-941.
33. Kwan P, Poon WS, Ng HK, et al. 
(2008). Multidrug resistance in 
epilepsy and polymorphisms in the 
voltage-gated sodium channel genes 
S C N 1 A ,  S C N 2 A ,  a n d  S C N 3 A : 
corre la t ion  among phenotype, 
genotype, and mRNA expression. 
Pharmacogenet Genomics 18: 989-
898.
34. Abe T, Seo T, Ishitsu T, Nakagawa T, 
Hor i  M,  Nakagawa K (2008) . 
A s s o c i a t i o n  b e t w e e n  S C N 1 A 
p o l y m o r p h i s m  a n d 
carbamazepine resistant epilepsy. Br 
J Clin Pharmacol 66 : 304-307.
35. Balan S, Vellichirammal NN, Banerjee 
M, Radhakrishnan K (2012). Failure to 
ﬁnd association between febrile 
seizures and SCN1A rs3812718 
polymorphism in south Indian patients 
with mesial temporal lobe epilepsy 
and hippocampal sclerosis. Epilepsy 
Res 101:288-292.
36. Bethmann K, Fritschy JM, Brandt C, 
Löscher W (2008). Antiepileptic drug 
resistant rats differ from drug 
responsive rats in GABA  receptor 
A
subunit expression in a model of 
temporal lobe epilepsy. Neurobiol Dis  
31:169-187.
37. Kumari R, Lakhan R, Kalita J, Misra 
U, Mittal B (2010). Association of 
alpha subunit of GABA< sub> 
A</sub> receptor subtype gene 
po lymorph i sms  wi th  ep i l epsy 
susceptibility and drug resistance in 
north Indian population. Seizure 19, 
237-241.
38. Kinirons P, Cavalleri GL, Singh R, et 
a l .  (2006)  A pharmacogenet ic 
exploration of vigabatrin-induced 
visual ﬁeld constriction. Epilepsy Res 
70 : 144-152.
39.Cavaller i  GL,  McCormack M, 
Alhusaini S, Chaila E, Delanty N  
(2011). Pharmacogenomics and 
e p i l e p s y :  t h e  r o a d  a h e a d . 
Pharmacogenomics 12: 1429-1447.
40. Zhang Y, Wang J, Zhao LM, et al. 
(2011) Strong association between 
HLA-B*1502 and carbamazepine-
induced Stevens-Johnson syndrome 
and toxic epidermal necrolysis in 
mainland Han Chinese patients. Eur J 
Clin Pharmacol 67: 885-887.
41. Löscher W, Klotz U, Zimprich F, 
Schmidt D (2009). The clinical impact 
of pharmacogenetics on the treatment 
of epilepsy. Epilepsia 50: 1-23.
42. Cavalleri GL, Weale ME, Shianna KV, 
et al. (2007). Multicentre search for 
genetic susceptibility loci in sporadic 
epilepsy syndrome and seizure types: a 
case-control study. Lancet Neurol 6: 
970-980.
43.Cardon LR, Palmer LJ (2003). 
Population stratiﬁcation and spurious 
allelic association. Lancet 361 : 598-
604.
44.Daly AK (2010). Genome-wide 
a s s o c i a t i o n  s t u d i e s  i n 
pharmacogenomics. Nat Rev Genet 
11: 241-246.
Kurupath Radhakrishnan19
